Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
ZIKA VIRUS ANTIBODY, IGM |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3534 Geisinger Epic ID: 121977 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
3 mL serum (minimum 1 mL) | |
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Blood collection tube should be centrifuged as soon as possible and serum transferred to a plastic transfer tube in order to avoid hemolysis | |
Transport temperature: |
Frozen. | |
Specimen stability: |
Room temperature: Unacceptable. Refrigerated: 7 days. Frozen: 30 days. | |
Rejection criteria: |
Plasma • Serum received in a frozen serum separator tube • Serum received in an unspun serum separator tube. Serum received in a standard red-top tube (not transferred to plastic transfer tube). Grossly lipemic. Gross hemolysis. | |
TEST DETAILS |
||
CPT code(s): |
86794 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Methodology: |
Immunoassay |
|
Synonyms: |
Quest test code 94264 ZIKAVM
|
|
Clinical significance: |
The Zika Virus Antibody (IgM) assay is intended for the qualitative detection of Zika virus IgM antibodies in human sera collected from individuals meeting CDC Zika virus clinical criteria and/or CDC Zika virus epidemiological criteria: The Zika Virus Antibody (IgM) assay results are for the presumptive detection of IgM antibodies to Zika virus (ZIKV). Reactive results are not definitive for diagnosis of Zika virus infection. False positive results are possible in patients with a history of infection with other Flaviviruses. Confirmation of the presence of anti-Zika IgM antibodies requires additional testing according to the latest CDC testing algorithms for the diagnosis of Zika virus infection. Within the United States and its territories, presumptive positive Zika test results are reported, as required, to the appropriate public health authorities. Results of the Zika Virus Antibody (IgM) test cannot be used as the sole basis of patient management decisions and must be combined with clinical observations, patient history, epidemiological information, and other laboratory evidences. Zika IgM levels over the course of illness are not well characterized. Negative results do not preclude the possibility of Zika virus infection, past or present. Negative results may be seen in specimens collected before detectable levels of IgM antibody develop or after the window of detectable IgM is present. |